13F filer · CIK 1652044 ↗

Alphabet Inc.

You are looking at Q1 2020. See the latest, Q2 2026 →

Reported value

$1.52B

−7.8% on the quarter before

Positions

3 new · 2 sold out

Top 10

94.7%

of the value

Est. gain

−$93.5M

on stocks held all quarter

Est. return

−6.3%

on those stocks since Q4 2019

Filed

Nov 15, 2022

On SEC EDGAR ↗

Positions as of Mar 31, 2020, from Alphabet Inc.'s 13F filing with the SEC. A 13F lists a manager's US-listed stocks and options at a quarter end and is filed up to 45 days later, so the fund may hold something else today. It leaves out short positions, cash and holdings outside the US.

Portfolio at a glance

New
Added
Cut
Same
Options

Each tile is a position, sized by its share, colored by what the fund did with it since Q4 2019. Striped tiles are options.

Jd Com Inc36%

Lyft Inc23%

Dexcom Inc14%

1life Healthcare Inc7.4%

Arcus Biosciences Inc4.6%

Vir Biotechnology Inc3.7%

Slack Technologies Inc.2.3%

Magenta Therapeutics Inc1.4%

Schrödinger1.3%

Rapt Therapeutics Inc1.2%

0.8%

0.6%

Jd Com Inc36%

Lyft Inc23%

Dexcom Inc14%

1life Healthcare Inc7.4%

Arcus Biosciences Inc4.6%

Vir Biotechnology Inc3.7%

Slack Technologies Inc.2.3%

Magenta Therapeutics Inc1.4%

Schrödinger1.3%

Rapt Therapeutics Inc1.2%

0.8%

0.6%

Largest buys

Since Q4 2019, by estimated size: the change in shares at the quarter-end price, since a 13F gives no trade prices. Percentages are the position's share of the portfolio, before and after.

1life Healthcare Inc~$112.2MNew · 0.0% → 7.4%+6,183,154 shares
Schrödinger~$19.3MNew · 0.0% → 1.3%+448,722 shares
Beam Therapeutics Inc~$11.9MNew · 0.0% → 0.8%+663,691 shares
Fulcrum Therapeutics Inc~$142,122Added · 0.7% → 0.6%+11,904 shares

Largest sells

Since Q4 2019, by estimated size: the change in shares at the quarter-end price, since a 13F gives no trade prices. Percentages are the position's share of the portfolio, before and after.

Uber~$104.4MCut · 6.8% → 0.1%−3,739,656 shares
Forty Seven Inc~$40.6MSold out · 2.5% → 0.0%−1,030,644 shares
Cloudflare~$27.9MSold out · 1.7% → 0.0%−1,632,519 shares

Holdings

As of Mar 31, 2020. Changes are in shares against Dec 31, 2019, so a price move alone never reads as a buy or a sale.

Positions, sorted by share of the portfolio
#	Holding		% prev	Value	Shares		Price	Prev price
1	Jd Com IncSPON ADR CL A · shares 0% · price +15.0%	36.0%	28.9%	$548.9M	13.6M	0%	$40.50	$35.23	+15.0%	+$71.4M
2	Lyft IncCL A COM · shares 0% · price −37.6%	22.6%	33.4%	$344.5M	12.8M	0%	$26.85	$43.02	−37.6%	−$207.4M
3	Dexcom IncCOM · shares 0% · price +23.1%	14.2%	10.7%	$216.9M	805,681	0%	$269.27	$218.74	+23.1%	+$40.7M
4	1life Healthcare IncCOM · shares New	7.4%	—	$112.2M	6.2M	New	$18.15	—	—	—
5	Arcus Biosciences IncCOM · shares 0% · price +37.4%	4.6%	3.1%	$70.1M	5.0M	0%	$13.88	$10.10	+37.4%	+$19.1M
6	Vir Biotechnology IncCOM · shares 0% · price +172.5%	3.7%	1.3%	$57.1M	1.7M	0%	$34.27	$12.57	+172.5%	+$36.2M
7	Slack Technologies Inc.COM CL A · shares 0% · price +19.4%	2.3%	1.8%	$34.9M	1.3M	0%	$26.84	$22.48	+19.4%	+$5.7M
8	Magenta Therapeutics IncCOM · shares 0% · price −58.6%	1.4%	3.1%	$21.0M	3.3M	0%	$6.28	$15.16	−58.6%	−$29.7M
9	SchrödingerCOM · shares New	1.3%	—	$19.3M	448,722	New	$43.12	—	—	—
10	Rapt Therapeutics IncCOM · shares 0% · price −23.0%	1.2%	1.4%	$17.8M	836,059	0%	$21.27	$27.61	−23.0%	−$5.3M
11	Beam Therapeutics IncCOM · shares New	0.78%	—	$11.9M	663,691	New	$18.00	—	—	—
12	CrowdStrikeCL A · shares 0% · price +11.6%	0.62%	0.52%	$9.5M	171,020	0%	$55.68	$49.87	+11.6%	+$993,000
13	Spero Therapeutics IncCOM · shares 0% · price −16.0%	0.59%	0.65%	$9.0M	1.1M	0%	$8.08	$9.61	−16.0%	−$1.7M
14	Fulcrum Therapeutics IncCOM · shares +1.7% · price −28.3%	0.57%	0.72%	$8.7M	726,189	+1.7%	$11.94	$16.64	−28.3%	−$3.4M
15	Cortexyme IncCOM · shares 0% · price −18.8%	0.57%	0.64%	$8.6M	189,122	0%	$45.61	$56.14	−18.8%	−$2.0M
16	SnapCL A · shares 0% · price −27.2%	0.41%	0.52%	$6.2M	523,710	0%	$11.89	$16.33	−27.2%	−$2.3M
17	Gritstone Oncology IncCOM · shares 0% · price −35.1%	0.35%	0.50%	$5.4M	929,022	0%	$5.82	$8.97	−35.1%	−$2.9M
18	Alector IncCOM · shares 0% · price +40.1%	0.28%	0.18%	$4.2M	175,866	0%	$24.13	$17.23	+40.1%	+$1.2M
19	Autolus Therapeutics PlcSPON ADS · shares 0% · price −54.6%	0.27%	0.56%	$4.2M	699,352	0%	$5.99	$13.20	−54.6%	−$5.0M
20	Evelo Biosciences IncCOM · shares 0% · price −7.5%	0.26%	0.26%	$4.0M	1.1M	0%	$3.75	$4.06	−7.5%	−$324,000
21	Cloudera IncCOM · shares 0% · price −32.3%	0.22%	0.30%	$3.4M	427,710	0%	$7.87	$11.63	−32.3%	−$1.6M
22	Ideaya Biosciences IncCOM · shares 0% · price −45.1%	0.20%	0.34%	$3.1M	753,187	0%	$4.12	$7.50	−45.1%	−$2.5M
23	Mohawk Group Hldgs IncCOM · shares 0% · price −71.3%	0.12%	0.38%	$1.8M	1.1M	0%	$1.69	$5.89	−71.3%	−$4.4M
24	UberCOM · shares −99% · price −6.1%	0.08%	6.8%	$1.2M	41,585	−99%	$27.92	$29.74	−6.1%	−$75,737
25	Dropbox IncCL A · shares 0% · price +1.3%	0.02%	0.01%	$236,000	13,033	0%	$18.11	$17.88	+1.3%	+$3,000
	Total · 25 positions	100%		$1.52B						−$93.5M

The filing on SEC EDGAR ↗

Price is a stock's reported value over its shares at the quarter end. The estimated gain is the shares held at both quarter ends times the change in that price: shares bought or sold during the quarter add nothing, options are left out, and a stock split is read into the earlier share count and price.

What made money

From Q4 2019 to Q1 2020: 22 stocks held throughout, down $93.5M (−6.3%).

Jd Com Inc+$71.4M+15%
Dexcom Inc+$40.7M+23%
Vir Biotechnology Inc+$36.2M+173%
Arcus Biosciences Inc+$19.1M+37%
Slack Technologies Inc.+$5.7M+19%
Mohawk Group Hldgs Inc−$4.4M−71%
Autolus Therapeutics Plc−$5.0M−55%
Rapt Therapeutics Inc−$5.3M−23%
Magenta Therapeutics Inc−$29.7M−59%
Lyft Inc−$207.4M−38%

Estimated as in the holdings table: shares held at both quarter ends times the change in price; options left out.

Reported value by quarter

The total value of each quarter's 13F at that quarter end. It moves with prices as well as with buying and selling. Pick a quarter to see what the fund held then.

$110.00B$55.00B$0

Q1 201642 quartersQ2 2026

Every quarter's filing

Each quarter's 13F filing, newest first
Quarter	Filed	Reported value	Positions	Filing
Q2 2026	Aug 7, 2026	$99.08B+2,367%	28	SEC ↗
Q1 2026	May 8, 2026	$4.02B+56%	26	SEC ↗
Q4 2025	Feb 13, 2026	$2.58B+7%	29	SEC ↗
Q3 2025	Nov 7, 2025	$2.41B+13%	37	SEC ↗
Q2 2025	Aug 1, 2025	$2.14B+35%	36	SEC ↗
Q1 2025	May 2, 2025	$1.58B−8%	40	SEC ↗
Q4 2024	Feb 7, 2025	$1.72B−7%	40	SEC ↗
Q3 2024	Nov 8, 2024	$1.84B−7%	42	SEC ↗
Q2 2024	Aug 2, 2024	$1.97B−21%	42	SEC ↗
Q1 2024	May 3, 2024	$2.51B+17%	43	SEC ↗
Q4 2023	Feb 9, 2024	$2.16B+39%	44	SEC ↗
Q3 2023	Nov 13, 2023	$1.56B−16%	45	SEC ↗
Q2 2023	Aug 4, 2023	$1.86B+3%	47	SEC ↗
Q1 2023	May 11, 2023	$1.80B+5%	49	SEC ↗
Q4 2022	Feb 14, 2023	$1.72B−12%	51	SEC ↗
Q3 2022	Nov 15, 2022	$1.96B+6%	49	SEC ↗
Q2 2022	Nov 15, 2022	$1.84B−40%	55	SEC ↗
Q1 2022	Nov 15, 2022	$3.08B−26%	60	SEC ↗
Q4 2021	Nov 15, 2022	$4.14B−2%	58	SEC ↗
Q3 2021	Nov 15, 2022	$4.22B−14%	43	SEC ↗
Q2 2021	Nov 15, 2022	$4.91B+98%	36	SEC ↗
Q1 2021	Nov 15, 2022	$2.48B+19%	32	SEC ↗
Q4 2020	Nov 15, 2022	$2.08B−2%	31	SEC ↗
Q3 2020	Nov 15, 2022	$2.13B−2%	24	SEC ↗
Q2 2020	Nov 15, 2022	$2.17B+42%	24	SEC ↗
Q1 2020	Nov 15, 2022	$1.52B−8%	25	SEC ↗
Q4 2019	Nov 15, 2022	$1.65B−50%	24	SEC ↗
Q3 2019	Nov 15, 2022	$3.33B−37%	24	SEC ↗
Q2 2019	Nov 15, 2022	$5.27B+172%	22	SEC ↗
Q1 2019	Nov 15, 2022	$1.94B+129%	17	SEC ↗
Q4 2018	Nov 15, 2022	$845.8M−19%	17	SEC ↗
Q3 2018	Nov 15, 2022	$1.04B−12%	17	SEC ↗
Q2 2018	Nov 15, 2022	$1.19B+94%	17	SEC ↗
Q1 2018	Nov 15, 2022	$614.8M+67%	11	SEC ↗
Q4 2017	Nov 15, 2022	$368.6M+7%	8	SEC ↗
Q3 2017	Nov 15, 2022	$344.0M−1%	4	SEC ↗
Q2 2017	Nov 15, 2022	$347.4M+10%	4	SEC ↗
Q1 2017	Nov 15, 2022	$316.8M+8%	3	SEC ↗
Q4 2016	Nov 15, 2022	$292.8M+6%	2	SEC ↗
Q3 2016	Nov 15, 2022	$275.2M+31%	2	SEC ↗
Q2 2016	Nov 15, 2022	$209.8M−14%	3	SEC ↗
Q1 2016	Nov 15, 2022	$242.9M	5	SEC ↗